EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the Company will participate at the following upcoming conferences:

• Citi's 18th Annual BioPharma ConferenceForum: 1x1 Investor MeetingsDate: Wednesday, September 6, 2023

• H.C. Wainwright 25th Annual Global Investment ConferenceForum: Corporate PresentationDate: Monday, September 11, 2023Time: Available on-demand at 7:00 a.m. ET

• Baird 2023 Global Healthcare ConferenceForum: Fireside ChatDate: Wednesday, September 13, 2023Time: 12:50 p.m. ET

• 2023 Cantor Fitzgerald Global Healthcare ConferenceForum: Fireside ChatDate: Tuesday, September 26, 2023Time: 1:15 p.m. ET

• JonesTrading 2023 Healthcare SummitForum: Panel DiscussionDate: Tuesday, October 10, 2023Time: 1:45 p.m. ET

A webcast and subsequent archived replay of the presentations and panel discussion may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary erodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com.

Investors:Christina TartagliaStern IRDirect: 212-698-8700[email protected]

Media ContactAmy PhillipsGreen Room CommunicationsDirect: 412-327-9499[email protected]

Source: EyePoint Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FuelCell Energy Investors: Kehoe Law Firm Investigates Fit Energy Agreement Disclosures – FCEL
• Penguin Solutions to Showcase AI Infrastructure and Memory Solutions at AI Infra Summit 2026
• Caesarstone Sustainability Report: ESG Considerations with Partner Selection